Effectiveness and cost of risperidone and olanzapine for schizophrenia: A systematic review

CNS Drugs

Volumn 19, Issue 5, 2005, Pages 393-410

  Hargreaves, William A ^a,c   Gibson, Joseph P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Marion County Health Department   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; BENZODIAZEPINE DERIVATIVE;

AGRANULOCYTOSIS; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ANTICHOLINERGIC EFFECT; COGNITION; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXTRAPYRAMIDAL SYNDROME; FOLLOW UP; GALACTORRHEA; HEALTH CARE COST; HISTAMINE RELEASE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPOTENSION; LIVER; LONG TERM CARE; MEDLINE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SYMPTOM; URINARY HESITANCY; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST; ECONOMICS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COSTS AND COST ANALYSIS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 22444438842     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519050-00003     Document Type: Review

References (54)

1. Gold MR, Russell LB, Siegel JE, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996
2. Drummond M, O'Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
3. Hargreaves WA, Shumway MS, Hu T-W, et al. Cost-outcome methods for mental health. San Diego: Academic Press, 1998
4. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995; 31: 57-65
5. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57: 66-76
6. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64
7. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59: 17-22
8. Luchins DJ, Klass D, Hanrahan P, et al. Alteration in the recommended dosing schedule for risperidone. Am J Psychiatry 1998; 155: 365-6
9. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
10. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55: 250-8
11. Allison DB, Mentore JL, Chandler LP, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96
12. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100
13. Masand P. Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 2000; 1: 377-89
14. Masand P, Wang X, Gupta S, et al. Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. Prim Care Companion J Clin Psychiatry 2002; 4: 70-3
15. Meyer J. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-33
16. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19: 316-21
17. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-63
18. Koro C, Fedder D, L'Italien G, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021-6
19. Koro C, Fedder D, L'Italien G, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2003; 326: 283-7
20. Fuller M, Shermock K, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003; 23: 1037-43
21. Ried L, Renner B, Bengtson M, et al. Weight change after an atypical antipsychotic switch. Ann Pharmacother 2003; 37: 1381-6
22. Volavka J, Czobor P, Cooper T, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65: 57-61
23. Lindenmayer J, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-6
24. Bilder R, Goldman R, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018-28
25. Purdon S, Woodward N, Lindborg S, et al. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 2003; 169: 390-7
26. Harvey P, Napolitano J, Mao L, et al. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry 2003; 18: 820-9
27. Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. Psychiatr Serv 1999; 50: 163-4
28. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharm 1997; 17: 407-18
29. Conley R, Mahmoud R, on behalf of The Risperidone Study Group. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158: 765-74
30. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-62
31. Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002; 28: 589-605
32. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003; 61: 303-14
33. Ho B-C, Miller D, Nopoulos P, et al. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60: 658-63
34. Sacristán JA, Gómez JC, Montejo AL, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin Ther 2000; 22: 583-99
35. Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001; 62: 749-56
36. Kasper S, Rosillon D, Duchesne I, et al. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 179-87
37. Rosenheck R, Leslie D, Sernyak M. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 2003; 160: 310-5
38. Byerly M, Weber M, Brooks D, et al. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003; 54: 742-4
39. Rascati K, Johnsrud M, Crismon M, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003; 21: 683-97
40. Liu CY, Chiu NY, Wu CK, et al. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int Clin Psychopharmacol 2003; 18: 49-51
41. Gibson P, Damler R, Jackson E, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004; 7: 22-35
42. Jeste D, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003; 11: 638-47
43. Ritchie C, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003; 18: 432-40
44. Thompson PDR, Micromedex, Cohen HE. Drug Topics Red Book. Stamford (CT): Thompson Healthcare, 2004
45. Risperdal (risperidone) and Zyprexa (olanzapine) prescribing information [online]. Available from URL: http://www.mentalhealth.com [Accessed 2005 Mar 30]
46. Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18: 567-79
47. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52: 1510-014
48. Wei LJ, Lachin JM. Properties of the urn randomization method in clinical trials. Control Clin Trials 1988; 9: 345-64
49. Fuller MA, Shermock KM, Secic M, et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv 2002; 53: 855-60
50. Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface 2002; 15: 75-81
51. Zhao Z. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. Curr Med Res Opin 2004; 20: 1039-48
52. Russo PA, Smith MW, Namjoshi M. Healthcare costs for schizophrenia patients started on olanzapine versus risperidone. Am J Health-Syst Pharm 2005; 62: 610-5
53. Stroup T, McEvoy J, Swartz M, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 20: 15-31
54. Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE) [online]. Available from URL: http://www.catie.unc.edu [Accessed 2005 May 3]